Cancer Treatment Reviews
Volume 28, Issue 6 , Pages 275-290 , December 2002

Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer

  • Fatima Cardoso
    • ,
  • Angelo Di Leo
    • ,
  • Martine J. Piccart

      Affiliations

    • Corresponding Author InformationCorrespondence to: Martine J. Piccart MD, PhD, Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo, 215 1000 Brussels, Belgium, Tel.: +32-2/541-32-06; Fax: +32-2/538-08-58

References 

  1. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1999; 8351: 1451–1467
  2. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930–942
  3. Early Breast Cancer Trialists Collaborative Group. 2000 analysis overview results. Fifth Meeting of the Early Breast Cancer Trialists Collaborative Group. Oxford; UK, 21–23 September 2000
  4. National Institutes of Health Consensus Development Conference Statement. Treatment of early breast cancer. JAMA 1991; 265: 391–395
  5. The National Institutes of Health Consensus Development Conference. J Natl Cancer Inst Monographs 2001; 30: 1–152
  6. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting Highlights: International consensus panel on treatment of primary breast cancer. J. Natl. Cancer Inst. 1998;90:1601–1608
  7. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Clin. Oncol. 2001;19:3817–3827
  8. Piccart MJ, Goldhirsch A, Gelber RD. Controversies in adjuvant systemic therapy of breast cancer: introduction. Educational Book of the thirty-eight annual meeting of the American Society of Clinical Oncology. 2002;138–143
  9. Piccart MJ, Cardoso F, Di Leo A, Awada A, Gelber RD. Areas of controversy in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. Educational Book of the thirty-eight annual meeting of the American Society of Clinical Oncology. 2002;144–155
  10. Harvey JM, Clark GM, Osborne CK, et al.  Oestrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999;17:1474–1481
  11. Piccart MJ, Mano M, Lohrisch C, Di Leo A. Herceptin for the treatment of breast cancer: what we know and what we still need to learn. Cancer futures. 2002;1(2–3):73–79
  12. Fisher B, Dignam J, Tan-Chiu E, Anderson S, et al.  Prognosis and treatment of patients with breast tumours of one centimeter or less and negative axillary lymph nodes. J. Natl. Cancer Inst. 2001;93:112–120
  13. Rosen PP, Groshen S, et al.  A long-term follow-up of survival in stage I. () and stage II () breast carcinoma. J. Clin. Oncol. 1989;7:355–366
  14. Leitner SP, Swern AS, Weinberger D, et al.  Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0). Cancer. 1995;76:2266–2274
  15. Joensuu H, Pylkkänen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer. 1999;85:2183–2189
  16. Rosner D, Lane WW. Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res. Treat. 1993;25:127–139
  17. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node negative breast cancer a study of 826 patients with long-term follow-up. J. Clin. Oncol. 1995;13:1144–1151
  18. Hery M. Long term outcome of 2683 patients with node negative (N-) breast cancer, with no systemic adjuvant therapy: a nonlinear evolution. Proc. Am. Soc. Clin. Oncol. 2001;20:40a; (abstract 156)
  19. Berg SW, Robbins GF. Factors influencing short and long-term survival of breast cancer patients. Surg. Gynecol. Obstet. 1966;122:1311–1316
  20. Adair F, Berg J, Joubert L, et al.  Long-term follow-up of breast cancer patients. A 30-year report. Cancer. 1974;33:1145–1150
  21. Fisher B, Slack NH, Bross IDJ. Cancer of the breast: size of neoplasm and prognosis. Cancer. 1969;24:1071–1080
  22. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J. Natl. Cancer Inst. 2002;94:39–49
  23. Jänicke F, Schmitt M, Pache L, et al.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res. Treat. 1993;24:195–208
  24. Harbeck N, Dettmar P, Thomssen C, et al.  Risk-group discrimination in node negative breast cancer using invasion and proliferation markers: 6 year median follow-up. Br. J. Cancer. 1999;80:419–426
  25. Harbeck N, Thomssen C, Berger U, et al.  Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res. Treat. 1999;54:147–157
  26. Jänicke F, Thomssen C, Pache L, et al.  Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node negative breast cancer patients. In:  Schmitt M,  Graeff H,  Janicke F editor. Prospects in diagnosis and treatment of cancer. Amsterdam (The Netherlands): Elsevier Science; 1994;p. 207–218
  27. Jänicke F, Prechtl A, Thomssen C, et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type1. J. Natl. Cancer Inst. 2001;93:913–920
  28. Sweep CG, Geurts-Moespot J, Grebenschikov N, et al.  External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasmonigen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer. 1998;78:1434–1441
  29. Benraad TJ, Geurts-Moespot J, Grondahl-Hansen J, et al.  Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur. J. Cancer. 1996;32A:1371–1381
  30. Haybittle JL, Blamey RW, Elston CW, et al.  A prognostic index in primary breast cancer. Br. J. Cancer. 1982;45:361–366
  31. Todd JH, Dowle C, Williams MR, et al.  Confirmation of a prognostic index in primary breast cancer. Br. J. Cancer. 1987;56:489–492
  32. Galea MH, Blamey RW, Elston CE, et al.  The Notthingham prognostic index in primary breast cancer. Breast Cancer Res. Treat. 1992;22:207–219
  33. D’Eredita G, Giardina C, Martellotta M, et al.  Prognostic factors in breast cancer: the predictive value of the Nottingham prognostic index in patients with a long-term follow-up that were treated in a single institution. Eur. J. Cancer. 2001;37:591–596
  34. Sørlie T, Perou CM, Tibshirani R, et al.  Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 2001;98(19):10869–10874
  35. West M, Blanchette C, Dressman H, et al.  Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA. 2001;98(20):11462–11467
  36. van’t Veer LJ, van de Vrijver MJ, Dai H, et al.  Expression profiling predicts poor outcome of disease in young breast cancer patients. Eur. J. Cancer. 2001;34(suppl 6):5271; (abstract 1000)
  37. van de Vijver MJ, He YD, Van ’t Veer LJ, et al.  Gene expression profiling accurately predicts metastasis-free survival in breast cancer, also in lymph node positive patients. Proc. Am. Soc. Clin. Oncol. 2002;21:64b; (abstract 2067)
  38. International Breast Cancer Study Group (IBCSG): Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Nat Cancer Ins 2002; 94: 1054–1065
  39. Fargeot P, Roche H, Bonneterre JM, et al.  Disease-free survival (DFS) advantage of weekly epirubicin plus tamoxifen vs tamoxifen alone as adjuvant treatment of operable, node-positive (N+) elderly breast cancer (BC) patients (pts): 5-year follow-up results of the French Adjuvant Study Group, FASG-08 trial. Proc. Am. Soc. Clin. Oncol. 2002;21:37a; (abstract 145)
  40. Bonetti M, Gelber RD, Goldhirsch A, et al.  Features that predict responsiveness to chemotherapy and endocrine therapies. The Breast. 2001;10:147–157
  41. Goldhirsch A, Gelber RD, Yothers G, et al.  Adjuvant therapy of very young women with breast cancer: need for tailored treatments. J. Natl. Cancer Inst. Monographs. 2001;30:44–51
  42. Henderson IC, Berry D, Demetri G, et al.  Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but no from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 1998;17:101a; (abstract 390A)
  43. Piccart MJ, Lohrisch C, Duchateau L, Buyse M. Taxanes in the adjuvant setting: why not yet?. J. Natl. Cancer Inst. Monographs. 2001;30:88–95
  44. Di Leo A, Cardoso F, Scohy S, Piccart MJ. Predictive molecular markers: a new window of opportunity in the adjuvant therapy of breast cancer. In: Naboltz JM, Tonkin K, Aapro MS, Buzdar AU (eds.), Breast Cancer Management – Application of Evidence to Patient Care. United Kingdom, 2nd edn. 2002, in press
  45. Ellis MJ, Coop A, Singh B, et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, oestrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001;19(18):3808–3816
  46. Cardoso F, Atalay G, Piccart MJ. Optimising anthracycline therapy for node positive breast cancer. Am. J. Cancer. 2002;1(4):257–268
  47. Hutchins L, Green S, Ravdin P, et al.  CMF versus CAF with and without TAMoxifen in high-risk node negative breast cancer patients and a natural history follow-up study in low-risk node negative patients: first results of Intergroup trial INT 0102. Proc. Am. Soc. Clin. Oncol. 1998;17:1a; (abstract 2)
  48. Fisher B, Anderson S, Wolmark N, et al.  Chemotherapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: results from NSABP B23. J. Clin. Oncol. 2001;19:931–942
  49. Mouridsen HT, Andersen J, Anderson M, et al.  Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc. Am. Soc. Clin. Oncol. 1999;18:68a; (abstract 254)
  50. Piccart MJ, Di Leo A, Beauduin M, et al.  Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J. Clin. Oncol. 2001;19:3103–3110
  51. Bianco AR, Costanzo R, Di Lorenzo G, et al.  The Mam-1 GOCSI trial: a randomized trial with factorial design of chemo-endocrine adjuvant treatment in doe-positive (N+) early breast cancer (EBC). Proc. Am. Soc. Clin. Oncol. 2001;20:27a; (abstract 104)
  52. Camaggi CM, Comparsi R, Strocchi E, et al.  Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother. Pharmacol. 1988;21(3):221–228
  53. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat. Rev. 1993;18:197–228
  54. Findlay BP, Walker-Dllks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev. Control. 1998;2:140–146
  55. Budman DR, Berry DA, Cirrincione CT, et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukaemia Group B. J. Natl. Cancer Inst. 1998;90:1205–1211
  56. Bonneterre J, Roche H, Bremond A, et al.  Results of a randomized trial of adjuvant chemotherapy with FEC50 vs FEC100 in high risk node-positive breast cancer patients. Proc. Am. Soc. Clin. Oncol. 1998;17:124a; (abstract 473)
  57. Bremond A, Kerbrat P, Fumoleau P, et al.  Five year follow-up results of a randomized trial testing the role of the dose intensity and duration of chemotherapy in node-positive premenopausal breast cancer patients. Proc. Am. Soc. Clin. Oncol. 1996;15:113a; abstract 119
  58. Wood WC, Budman DR, Korzun AH, et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med. 1994;330:1253–1259
  59. French Adjuvant Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5 year follow-up results of French adjuvant study group 05 randomized trial. J Clin Oncol 2001; 19: 602–611
  60. Fumoleau P, Brémond A, Kerbrat P, et al.  Better outcome of premenopausal node-positive (N+) breast cancer patients (pts) treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: eight year follow-up results of FASG 01. Proc. Am. Soc. Clin. Oncol. 1999;18:67a; (abstract 252)
  61. Colleoni M, Bonetti M, Coates AS, et al.  Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumours not expressing oestrogen receptors. J. Clin. Oncol. 2000;18:584–590
  62. Tucker MA, Meadows AT, Boice JD, et al.  Leukaemia after therapy with alkylating agents for childhood cancer. J. Natl. Cancer Inst. 1987;78:459–464
  63. Chambers SK, Chopyk RL, Chambers JT, Schwartz PE, Duffy TP. Development of leukaemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer. 1989;64:2459–2461
  64. Praga C, Trave F. Epirubicin – secondary leukaemia monitoring plan preliminary report November 1998. Pharmacia and Upjohn, Phamacoviligance Data Safety Report
  65. Praga C. Epirubicin – secondary leukaemia monitoring plan preliminary report. Addendum N 1, September 10, 1999. Pharmacia and Upjohn, Pharmacovigilance Data Safety Report
  66. Crump M, Tu D, Shepherd L, et al.  Risk of acute leukaemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 2001;69(3):247; (abstract 243)
  67. Smith RE, Bryant J, DeCells A, et al.  Acute myeloid leukaemia and myelodysplastic syndrome following doxorubicin–cyclophosphamide adjuvant therapy for operable breast cancer: the NSABP experience. Breast Cancer Treat. 2001;69(3):209
  68. Von Hoff DD, Rozencweig M, Piccart MJ. The cardiotoxicity of anticancer agents. Sem. Oncol. 1982;9:23–33
  69. Levine MN, Bramwell VH, Pritchard KI, et al.  Randomized trial of intensive cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1998;16:2651–2658
  70. Zambetti M, Moliterni A, Materazzo C, et al.  Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol. 2001;19:37–43
  71. Bonneterre JM, Roche H, Kerbrat P, et al.  Long-term cardiac follow-up in free of disease patients (pts) after receiving 6 FEC 50 vs 6 FEC 100 (fasg-05 trial) as adjuvant chemotherapy (CT) for node-positive (N+) breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 2002;39a; (abstract 154)
  72. Suter TM, Meier B. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel. Ann. Oncol. 2002;13:647–649
  73. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al.  Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. 2001;19:2746–2753
  74. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol. 2002;13:699–709
  75. Cardinale D, Sandri MT, Martinoni A, et al.  Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann. Oncol. 2002;13:710–715
  76. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885–1894
  77. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 677–683
  78. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node negative breast cancer. N Engl J Med 1989; 320: 491–496
  79. Colleoni M, Gelber S, Coates AS, et al.  Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node negative breast cancer. J. Clin. Oncol. 2001;19:4141–4149
  80. Henderson CI. Adjuvant chemotherapy: Taxanes – the “Pro” position. In: Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer, 2000
  81. Tan AR, Swain SM. Adjuvant chemotherapy for breast cancer: an update. Sem. Oncol. 2001;28(4):359–376
  82. Buzdar AU, Singletary SE, Valero V, et al.  Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer preliminary data of a prospective randomized trial. Clin. Cancer Res. 2002;8:1073–1079
  83. Mamounas EP. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary node. In: Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer, 2000
  84. NSABP, Pittsburgh, PA. The effect on primary tumour response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B 27. In: Oral session of the 24th Annual San Antonio Breast Cancer Symposium, December 2001
  85. Nabholtz JM, Pienkowski T, Mackey J, et al.  Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc. Am. Soc. Clin. Oncol. 2002;1:39a; (abstract 141)

☆ This paper is based on Dr Martine Piccart’s lecture at the Breast Cancer Education Section of the 2002 Meeting of the American Society of Clinical Oncology on “Controversies in Adjuvant Systemic Therapy of Breast Cancer”.

PII: S0305-7372(02)00091-9

Cancer Treatment Reviews
Volume 28, Issue 6 , Pages 275-290 , December 2002

Article Tools

* Image Usage & Resolution